Argireline

Argireline (Acetyl Hexapeptide-3, later renamed Acetyl Hexapeptide-8) is a synthetic hexapeptide that was one of the first peptides developed and marketed specifically as a topical anti-wrinkle cosmetic ingredient. Developed by the Barcelona-based company Lipotec in the early 2000s, Argireline quickly became one of the most commercially successful cosmetic peptides and helped establish the broader "cosmeceutical peptides" category in skincare.

Like Snap-8, Argireline targets the SNARE complex at the neuromuscular junction, mimicking a portion of the SNAP-25 protein. By competing for positions in the SNARE assembly, it reduces the efficiency of vesicle fusion and neurotransmitter release, leading to a modest reduction in muscle contraction intensity. This mechanism-based approach to wrinkle reduction provided a scientific narrative that resonated strongly with consumers seeking alternatives to injectable treatments.

Clinical studies on Argireline have shown measurable reductions in wrinkle depth with consistent topical application. In one frequently cited study, a 10% Argireline solution applied twice daily for 30 days reduced wrinkle depth by approximately 30% compared to baseline. While significant, this effect is modest compared to botulinum toxin injection, and it requires continuous application to maintain. The effects develop gradually over weeks and reverse upon discontinuation.

Argireline has become ubiquitous in the anti-aging skincare market, appearing in products ranging from mass-market moisturizers to premium serums. Its success paved the way for numerous other cosmetic peptides and demonstrated consumer appetite for science-based skincare ingredients. In 2021, The Ordinary (owned by Deciem/Estee Lauder) launched an Argireline solution that became one of the most viral skincare products on social media, introducing the peptide to a new generation of consumers.